The antidepressant desipramine requires the ABCB1 (Mdr1)-type p-glycoprotein to upregulate the glucocorticoid receptor in mice

Neuropsychopharmacology

Volumn 32, Issue 12, 2007, Pages 2520-2529

  Yau, Joyce L W ^a   Noble, June ^a   Thomas, Sarah ^b   Kerwin, Robert ^b   Morgan, Phillip E ^c   Lightman, Stafford ^d   Seckl, Jonathan R ^a   Pariante, Carmine M ^b  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c Medical Toxicology Unit   (United Kingdom)

^d UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

11beta hydroxysteroid dehydrogenase type 1; Antidepressant; Glucocorticoid receptor; Mineralocorticoid receptor; Multiple drug resistance; p glycoprotein

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; 11BETA HYDROXYSTEROID DEHYDROGENASE TYPE 1; CORTICOSTERONE; DESIPRAMINE; GLUCOCORTICOID RECEPTOR; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONGENIC STRAIN; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG TARGETING; GENE EXPRESSION; GENE EXPRESSION REGULATION; HIPPOCAMPUS; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; RECEPTOR GENE; RECEPTOR UPREGULATION;

ANALYSIS OF VARIANCE; ANIMALS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; ATP-BINDING CASSETTE TRANSPORTERS; CORTICOSTERONE; DESIPRAMINE; HIPPOCAMPUS; IN SITU HYBRIDIZATION; MALE; MICE; MICE, KNOCKOUT; RECEPTORS, GLUCOCORTICOID; RNA, MESSENGER; UP-REGULATION;

EID: 34948826840     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1301389     Document Type: Article

References (73)

1. Avella J, Lehrer M, Katz M, Minden E (2004). Two cases involving clomipramine intoxication. J Anal Toxicol 28: 504-508.
2. Banner KH, Cattaneo C, Le Net JL, Popovic A, Collins D, Gale JD (2004). Macroscopic, microscopic and biochemical characterisation of spontaneous colitis in a transgenic mouse, deficient in the multiple drug resistance 1a gene. Br J Pharmacol 143: 590-598.
3. Basta-Kaim A, Budziszewska B, Jaworska-Feil L, Tetich M, Kubera M, Leskiewicz M et al (2004). Mood stabilizers inhibit glucocorticoid receptor function in LMCAT cells. Eur J Pharmacol 495: 103-110.
4. Basta-Kaim A, Budziszewska B, Jaworska-Feil L, Tetich M, Kubera M, Leskiewicz M et al (2006). Antipsychotic drugs inhibit the human corticotropin-releasing-hormone gene promoter activity in neuro-2A cells-an involvement of protein kinases. Neuropsychopharmacology 31: 853-865.
5. Basta-Kaim A, Budziszewska B, Jaworska-Feil L, Tetich M, Leskiewicz M, Kubera M et al (2002). Chlorpromazine inhibits the glucocorticoid receptor-mediated gene transcription in a calcium-dependent manner. Neuropharmacology 43: 1035-1043.
6. Bickel MH, Brochon R, Friolet B, Herrmann B, Stofer AR (1967). Clinical and biochemical results of a fatal case of desipramine intoxication. Psychopharmacologia 10: 431-436.
7. Bolo NR, Hode Y, Nedelec JF, Laine E, Wagner G, Macher JP (2000). Brain pharmacokinetics and tissue distribution in vivo of fluvoxamine and fluoxetine by fluorine magnetic resonance spectroscopy. Neuropsychopharmacology 23: 428-438.
8. Budziszewska B, Jaworska-Feil L, Kajta M, Lason W (2000). Antidepressant drugs inhibit glucocorticoid receptor-mediated gene transcription - a possible mechanism. Br J Pharmacol 130: 1385-1393.
9. Budziszewska B, Jaworska-Feil L, Tetich M, Basta-Kaim A, Kubera M, Leskiewicz M et al (2004). Regulation of the human corticotropin- releasing-hormone gene promoter activity by antidepressant drugs in Neuro-2A and AtT-20 cells. Neuropsychopharmacology 29: 785-794.
10. Carroll BJ, Heath B, Jarrett DB (1975). Corticosteroids in brain tissue. Endocrinology 97: 290-300.
11. de Kloet ER, Vreugdenhil E, Oitzl MS, Joels M (1998). Brain corticosteroid receptor balance in health and disease. Endocr Rev 19: 269-301.
12. Flores BH, Kenna H, Keller J, Solvason HB, Schatzberg AF (2006). Clinical and biological effects of mifepristone treatment for psychotic depression. Neuropsychopharmacology 31: 628-636.
13. Glotzbach RK, Preskorn SH (1982). Brain concentrations of tricyclic antidepressants: single-dose kinetics and relationship to plasma concentrations in chronically dosed rats. Psychopharmacology (Berl) 78: 25-27.
14. Grauer MT, Uhr M (2004). P-glycoprotein reduces the ability of amitriptyline metabolites to cross the blood brain barrier in mice after a 10-day administration of amitriptyline. J Psychopharmacol 18: 66-74.
15. Heiske A, Jesberg J, Krieg JC, Vedder H (2003). Differential effects of antidepressants on glucocorticoid receptors in human primary blood cells and human monocytic u-937 cells. Neuropsychopharmacology 28: 807-817.
16. Herr AS, Tsolakidou AF, Yassouridis A, Holsboer F, Rein T (2003). Antidepressants differentially influence the transcriptional activity of the glucocorticoid receptor in vitro. Neuroendocrinology 78: 12-22.
17. Herr AS, Wochnik GM, Rosenhagen MC, Holsboer F, Rein T (2000). Rifampicin is not an activator of glucocorticoid receptor. Mol Pharmacol 57: 732-737.
18. Hirrlinger J, Konig J, Dringen R (2002). Expression of mRNAs of multidrug resistance proteins (Mrps) in cultured rat astrocytes, oligodendrocytes, microglial cells and neurones. J Neurochem 82: 716-719.
19. Holsboer F (2000). The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 23: 477-501.
20. Juruena MF, Cleare AJ, Papadopoulos AS, Poon L, Lightman S, Pariante CM (2006). Different responses to dexamethasone and prednisolone in the same depressed patients. Psychopharmacology (Berl) 189: 225-235.
21. Karssen AM, Meijer OC, van der Sandt I, de Boer AG, de Lange EC, de Kloet ER (2002). The role of the efflux transporter P-glycoprotein in brain penetration of prednisolone. J Endocrinol 175: 251-260.
22. Karssen AM, Meijer OC, van der Sandt I, Lucassen PJ, de Lange EC, de Boer AG et al (2001). Multidrug resistance P-glycoprotein hampers the access of cortisol but not of corticosterone to mouse and human brain. Endocrinology 142: 2686-2694.
23. Kunzel HE, Binder EB, Nickel T, Ising M, Fuchs B, Majer M et al (2003). Pharmacological and nonpharmacological factors influencing hypothalamic-pituitary-adrenocortical axis reactivity in acutely depressed psychiatric in-patients, measured by the Dex-CRH test. Neuropsychopharmacology 28: 2169-2178.
24. Lai M, McCormick JA, Chapman KE, Kelly PAT, Seckl JR, Yau JLW (2003). Differential regulation of corticosteroid receptors by monoamine neurotransmitters and antidepressant drugs in primary hippocampal culture. Neuroscience 118: 975-984.
25. Maes M, Song C, Lin AH, Bonaccorso S, Kenis G, De Jongh R et al (1999). Negative immunoregulatory effects of antidepressants: inhibition of interferon-gamma and stimulation of interleukin-10 secretion. Neuropsychopharmacology 20: 370-379.
26. Meaney MJ, Aitken DH, Bodnoff SR, Iny LJ, Tatarewicz JE, Sapolsky RM (1985). Early postnatal handling alters glucocorticoid receptor concentrations in selected brain regions. Behav Neurosci 99: 765-770.
27. Meijer OC, de Lange EC, Breimer DD, de Boer AG, Workel JO, de Kloet ER (1998). Penetration of dexamethasone into brain glucocorticoid targets is enhanced in mdr1A P-glycoprotein knockout mice. Endocrinology 139: 1789-1793.
28. Miller AH, Vogt GJ, Pearce BD (2002). The phosphodiesterase type 4 inhibitor, rolipram, enhances glucocorticoid receptor function. Neuropsychopharmacology 27: 939-948.
29. Mukherjee K, Knisely A, Jacobson L (2004). Partial glucocorticoid agonist-like effects of imipramine on hypothalamic-pituitary-adrenocortical activity, thymus weight, and hippocampal glucocorticoid receptors in male C57BL/6 mice. Endocrinology 145: 4185-4191.
30. Muller MB, Keck ME, Binder EB, Kresse AE, Hagemeyer TP, Landgraf R et al (2003). ABCB1 (MDR1)-type P-glycoproteins at the blood-brain barrier modulate the activity of the hypothalamic-pituitary-adrenocortical system: implications for affective disorder. Neuropsychopharmacology 28: 1991-1999.
31. Neigh GN, Nemeroff CB (2006). Reduced glucocorticoid receptors: consequence or cause of depression? Trends Endocrinol Metab 17: 124-125.
32. Nemeroff CB, Owens MJ (2002). Treatment of mood disorders. Nat Neurosci 5(Suppl): 1068-1070.
33. Okugawa G, Omori K, Suzukawa J, Fujiseki Y, Kinoshita T, Inagaki C (1999). Long-term treatment with antidepressants increases glucocorticoid receptor binding and gene expression in cultured rat hippocampal neurones. J Neuroendocrinol 11: 887-895.
34. Pariante CM (2004). Glucocorticoid receptor function in vitro in patients with major depression. Stress 7: 209-219.
35. Pariante CM (2006). The glucocorticoid receptor: part of the solution or part of the problem? J Psychopharmacol 20: 79-84.
36. Pariante CM, Hye A, Williamson R, Makoff A, Lovestone S, Kerwin RW (2003a). The antidepressant clomipramine regulates cortisol intracellular concentrations and glucocorticoid receptor expression in fibroblasts and rat primary neurones. Neuropsychopharmacology 28: 1553-1561.
37. Pariante CM, Kim RB, Makoff A, Kerwin RW (2003b). Antidepressant fluoxetine enhances glucocorticoid receptor function in vitro by modulating membrane steroid transporters. Br J Pharmacol 139: 1111-1118.
38. Pariante CM, Makoff A, Lovestone S, Feroli S, Heyden A, Miller AH et al (2001). Antidepressants enhance glucocorticoid receptor function in vitro by modulating the membrane steroid transporters. Br J Pharmacol 134: 1335-1343.
39. Pariante CM, Papadopoulos AS, Poon L, Cleare AJ, Checkley SA, English J et al (2004a). Four days of citalopram increase suppression of cortisol secretion by prednisolone in healthy volunteers. Psychopharmacology (Berl) 177: 200-206.
40. Pariante CM, Pearce BD, Pisell TL, Owens MJ, Miller AH (1997). Steroid-independent translocation of the glucocorticoid receptor by the antidepressant desipramine. Mol Pharmacol 52: 571-581.
41. Pariante CM, Thomas SA, Lovestone S, Makoff A, Kerwin RW (2004b). Do antidepressants regulate how cortisol affects the brain? 2003 Curt Richter Award Paper. Psychoneuroendocrinology 29: 423-447.
42. Peiffer A, Lapointe B, Barden N (1991a). Hormonal regulation of type II glucocorticoid receptor messenger ribonucleic acid in rat brain. Endocrinology 129: 2166-2174.
43. Peiffer A, Veilleux S, Barden N (1991b). Antidepressant and other centrally acting drugs regulate glucocorticoid receptor messenger RNA levels in rat brain. Psychoneuroendocrinology 16: 505-515.
44. Pepin MC, Beaulieu S, Barden N (1989). Antidepressants regulate glucocorticoid receptor messenger RNA concentrations in primary neuronal cultures. Brain Res Mol Brain Res 6: 77-83.
45. Pepin MC, Beaulieu S, Barden N (1990). Differential regulation by dexamethasone of glucocorticoid receptor messenger RNA concentrations in neuronal cultures derived from fetal rat hypothalamus and cerebral cortex. Cell Mol Neurobiol 10: 227-235.
46. Pepin MC, Pothier F, Barden N (1992). Antidepressant drug action in a transgenic mouse model of the endocrine changes seen in depression. Mol Pharmacol 42: 991-995.
47. Reul JM, Stec I, Soder M, Holsboer F (1993). Chronic treatment of rats with the antidepressant amitriptyline attenuates the activity of the hypothalamic-pituitary-adrenocortical system. Endocrinology 133: 312-320.
48. Rossby SP, Nalepa I, Huang M, Perrin C, Burt AM, Schmidt DE et al (1995). Norepinephrine-independent regulation of GRII mRNA in vivo by a tricyclic antidepressant. Brain Res 687: 79-82.
49. Sapolsky RM, McEwen BS (1985). Down-regulation of neural corticosterone receptors by corticosterone and dexamethasone. Brain Res 339: 161-165.
50. Schinkel AH, Mayer U, Wagenaar E, Mol CA, van Deemter L, Smit JJ et al (1997). Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc Natl Acad Sci USA 94: 4028-4033.
51. Schmidt TJ, Meyer AS (1994). Autoregulation of corticosteroid receptors. How, when, where, and why? Receptor 4: 229-257.
52. Seckl JR, Fink G (1992). Antidepressants increase glucocorticoid and mineralocorticoid receptor mRNA expression in rat hippocampus in vivo. Neuroendocrinology 55: 621-626.
53. Seckl JR, Walker BR (2001). Minireview: 11β-hydroxysteroid dehydrogenase type 1- a tissue-specific amplifier of glucocorticoid action. Endocrinology 142: 1371-1376.
54. Sisodiya SM, Lin WR, Harding BN, Squier MV, Thom M (2002). Drug resistance in epilepsy: expression of drug resistance proteins in common causes of refractory epilepsy. Brain 125: 22-31.
55. Sunshine I, Baeumler J (1963). A fatal case of poisoning with amitriptyline. Nature 199: 1103-1104.
56. Szabo D, Szabo Jr G, Ocsovszki I, Aszalos A, Molnar J (1999). Antipsychotic drugs reverse multidrug resistance of tumor cell lines and human AML cells ex-vivo. Cancer Lett 139: 115-119.
57. Uhr M, Grauer MT (2003). abcb1ab P-glycoprotein is involved in the uptake of citalopram and trimipramine into the brain of mice. J Psychiatr Res 37: 179-185.
58. Uhr M, Grauer MT, Holsboer F (2003). Differential enhancement of antidepressant penetration into the brain in mice with abcb1ab (mdr1ab) P-glycoprotein gene disruption. Biol Psychiatry 54: 840-846.
59. Uhr M, Holsboer F, Muller MB (2002). Penetration of endogenous steroid hormones corticosterone, cortisol, aldosterone and progesterone into the brain is enhanced in mice deficient for both mdr1a and mdr1b P-glycoproteins. J Neuroendocrinol 14: 753-759.
60. Uhr M, Steckler T, Yassouridis A, Holsboer F (2000). Penetration of amitriptyline, but not of fluoxetine, into brain is enhanced in mice with blood-brain barrier deficiency due to mdr1a P-glycoprotein gene disruption. Neuropsychopharmacology 22: 380-387.
61. van West D, Van Den EF, Del Favero J, Souery D, Norrback KF, Van Duijn C et al (2006). Glucocorticoid receptor gene-based SNP analysis in patients with recurrent major depression. Neuropsychopharmacology 31: 620-627.
62. Varga A, Nugel H, Baehr R, Marx U, Hever A, Nacsa J et al (1996). Reversal of multidrug resistance by amitriptyline in vitro. Anticancer Res 16: 209-211.
63. Wang X, Wu H, Lakdawala VS, Hu F, Hanson ND, Miller AH (2005). Inhibition of Jun N-terminal kinase (JNK) enhances glucocorticoid receptor-mediated function in mouse hippocampal HT22 cells. Neuropsychopharmacology 30: 242-249.
64. Weber CC, Eckert GP, Muller WE (2006). Effects of antidepressants on the brain/plasma distribution of corticosterone. Neuropsychopharmacology 31: 2443-2448.
65. Weber CC, Kressmann S, Ott M, Fricker G, Muller WE (2005). Inhibition of P-glycoprotein function by several antidepressants may not contribute to clinical efficacy. Pharmacopsychiatry 38: 293-300.
66. Weiss J, Dormann SM, Martin-Facklam M, Kerpen CJ, Ketabi-Kiyanvash N, Haefeli WE (2003). Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Ther 305: 197-204.
67. Welberg LA, Seckl JR, Holmes MC (2001). Prenatal glucocorticoid programming of brain corticosteroid receptors and corticotrophin-releasing hormone: possible implications for behaviour. Neuroscience 104: 71-79.
68. Yau JL, Noble J, Hibberd C, Seckl JR (2001). Short-term administration of fluoxetine and venlafaxine decreases corticosteroid receptor mRNA expression in the rat hippocampus. Neurosci Lett 306: 161-164.
69. Yau JL, Noble J, Seckl JR (1997). Site-specific regulation of corticosteroid and serotonin receptor subtype gene expression in the rat hippocampus following 3,4-methylenedioxy-methamphetamine: role of corticosterone and serotonin. Neuroscience 78: 111-121.
70. Yehuda R, Yang RK, Golier JA, Grossman RA, Bierer LM, Tischler L (2006). Effect of sertraline on glucocorticoid sensitivity of mononuclear leukocytes in post-traumatic stress disorder. Neuropsychopharmacology 31: 189-196.
71. Yehuda R, Yang RK, Golier JA, Tischler L, Liong B, Decker K (2004). Effect of topiramate on glucocorticoid receptor mediated action. Neuropsychopharmacology 29: 433-439.
72. Young AH, Gallagher P, Watson S, Del Estal D, Owen BM, Nicol FI (2004). Improvements in neurocognitive function and mood following adjunctive treatment with mifepristone (RU-486) in bipolar disorder. Neuropsychopharmacology 29: 1538-1545.
73. Young EA, Lopez JF, Murphy-Weinberg V, Watson SJ, Akil H (2003). Mineralocorticoid receptor function in major depression. Arch Gen Psychiatry 60: 24-28.